TGF-β inhibition enhanced the proinflammatory potential of TANs (N1), resulting in an increased expression of proinflammatory cytokines such as TNF-α and CCL3, cytotoxic CD8+ T lymphocyte activation, and direct killing of tumor cells dependent on ROS and the costimulatory molecule ICAM-1. The gene discussed is CD8A; the disease is neoplasm.